Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin

Alcohol Use Disorder Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01916941
• Other study ID #: 1K23AA021156-01A1
• Status: Completed
• Phase: N/A
• First received: August 1, 2013
• Last updated: October 12, 2017
• Start date: September 2013
• Est. completion date: September 2017

Study information

• Verified date: October 2017
• Source: University of New Mexico
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study uses neurobiological measures through brain imaging, neuropsychological measures, and selfreport measures to try to understand how an effective treatment for alcoholism works. On the whole, less than 50% of people with alcoholism get better with treatment. This study will help researchers develop better treatments for alcoholism because if the investigators know why the treatments the investigators use are working, and in whom the treatments work best, then the investigators may be able to make treatment more effective by targeting treatments to individuals who would be most likely to benefit and by guiding development of more effective treatments in the future.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 2017
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females age 18-65 meeting DSM-IV criteria for alcohol dependence in the past year;

2. seeking but not currently receiving treatment;

3. able to provide voluntary informed consent;

4. have at least 4 drinking days in the past 30 days

5. english-speaking

6. have a primary care physician or psychiatrist willing to continue prazosin if the patient tolerates it well and is finding it beneficial.

Exclusion Criteria:

1. severe neurological (e.g., head injury/stroke) conditions, Meniere's disease, narcolepsy, benign positional vertigo, heart disease or unstable angina, history of dysrhythmia/syncope, SBP<110, SBP>160, DBP>110, HR<55, HR>110, irregular heart rhythm, chronic renal or hepatic failure, pancreatitis or insulin-dependent diabetes, or other medical problems requiring immediate attention;

2. schizophrenia, schizoaffective disorder, PTSD, Bipolar I disorder, suicidal thoughts within the last month;

3. current dependence on another drug of abuse (except nicotine);

4. contraindications to MRI (e.g., pacemaker);

5. active legal problems with the potential to result in incarceration;

6. pregnancy or lactation, or child bearing age and not on birth control;

7. currently receiving treatment for alcohol dependence;

8. current use of psychoactive medications including SSRI's and other antidepressants, anti-craving medications, anxiolytics including benzodiazepines, antipsychotics, mood stabilizers or anticonvulsants;

9. history of seizures or DT's during alcohol withdrawal.

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder

Intervention

Drug:
• Prazosin

• Placebo

Locations

Country	Name	City	State
United States	University of New Mexico, Department of Psychiatry	Albuquerque	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
University of New Mexico

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week)		from 2-4 weeks and from 4-6 weeks